CD8A and neoplasm: Immunosuppression by PD-1 Treg is reversed with anti-PD-1 therapy, where Treg correlates with poor prognosis, and CD8+ memory T cells stay in liver and effectively attack tumor cells, therefore having a better prognosis [90] (Figure 3A).